Evidence map›Paper›PMID 31147819›Full record

ReviewStem cell reviews and reports2019

Enhancing the Therapeutic Potential of Mesenchymal Stem Cells with the CRISPR-Cas System.

Daniel Mendes Filho, Patrícia de Carvalho Ribeiro, Lucas Felipe Oliveira, Ana Luiza Romero Terra Dos Santos, Ricardo Cambraia Parreira, Mauro Cunha Xavier Pinto, Rodrigo Ribeiro Resende

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Daniel Mendes FilhoDepartment of Physiology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Patrícia de Carvalho RibeiroLaboratory of Immunology and Experimental Transplantation, São José do Rio Preto Medical School, São José do Rio Preto, São Paulo, Brazil.
Lucas Felipe OliveiraDepartment of Physiology, Biological and Natural Sciences Institute, Triangulo Mineiro Federal University, Uberaba, Minas Gerais, Brazil.
Ana Luiza Romero Terra Dos SantosDepartment of Physiology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Ricardo Cambraia ParreiraDepartment of Pharmacology, Biological Sciences Institute, Goias Federal University, Goiania, Goias, Brazil. rcparreira@ufg.br.ORCID 0000-0002-2769-7958
Mauro Cunha Xavier PintoDepartment of Pharmacology, Biological Sciences Institute, Goias Federal University, Goiania, Goias, Brazil.
Rodrigo Ribeiro ResendeDepartment of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Universidade de São Paulo · BRUniversidade Federal de Goiás · BRFaculdade de Medicina de São José do Rio Preto · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal do Triângulo Mineiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs), also known as multipotent mesenchymal stromal stem cells, are found in the perivascular space of several tissues. These cells have been subject of intense research in the last decade due to their low teratogenicity, as well as their ability to differentiate into mature cells and to secrete immunomodulatory and trophic factors. However, they usually promote only a modest benefit when transplanted in experimental disease models, one of the limitations for their clinical application. The CRISPR-Cas system, in turn, is highlighted as a simple and effective tool for genetic engineering. This system was tested in clinical trials over a relatively short period of time after establishing its applicability to the edition of the mammalian cell genome. Similar to the research evolution in MSCs, the CRISPR-Cas system demonstrated inconsistencies that limited its clinical application. In this review, we outline the evolution of MSC research and its applicability, and the progress of the CRISPR-Cas system from its discovery to the most recent clinical trials. We also propose perspectives on how the CRISPR-Cas system may improve the therapeutic potential of MSCs, making it more beneficial and long lasting.

Indexed as

CRISPR-Cas SystemsGene EditingImmunomodulationAnimalsDisease Models, AnimalHumansMesenchymal Stem CellsCell therapyCRISPR-CasGenetic engineeringMesenchymal stem cellsMesenchymal stromal cells

Identifiers

PMID31147819
OpenAlexW2947812703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.